Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC

Inclusion Criteria: 1. Voluntary participation and informed consent, aged 18-75; 2. Patients with HCC confirmed by histopathology or meeting the clinical diagnostic criteria in the 2019 edition of the diagnostic and therapeutic criteria for primary liver cancer; 3. BCLC stage C patients with vascular invasion and without extrahepatic metastasis; 4. Child Pugh liver function classification: A or B grade; 5. ECOG physical strength score was 0-2 points; 6. No previous systemic or local treatment, and the expected survival time is more than 3 months; 7. According to recist1.1, the patient must have at least one measurable target lesion that has passed CT or MRI examination, and the tumor imaging evaluation was conducted within 2 weeks before receiving the study drug; 8. Full organ and bone marrow function: WBC ≥ 3.0 × 109/L； NE≥1.5 × 109/L； PLT≥75 × 109/L； Liver and kidney function ALT and AST ≤ 5uln; TBIL≤2ULN； Albumin ≥ 28g / L; Cr≤1.5 ULN； International normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) exceeding the normal control range ≤ 4 seconds; Exclusion Criteria: 1. Hepatocholangiocarcinoma, mixed cell carcinoma and fibrolamellar cell carcinoma are known; 2. Uncontrollable ascites, hepatic encephalopathy or esophageal variceal bleeding; 3. Patients with hypertension who can not be reduced to normal range after antihypertensive drug treatment (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg); 4. Patients with myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmia, myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmia (QTc interval ≥ 450 ms) (QTc interval was calculated by fridericia formula); 5. Patients with history of gastrointestinal bleeding or definite tendency of gastrointestinal bleeding in the past 3 months, such as esophageal varices with bleeding risk, local active ulcer lesions, fecal occult blood ≥ +, can not be included in the group; 6. Pregnant or lactating women, patients with fertility are unwilling or unable to take effective contraceptive measures; 7. patients with a history of HIV infection; 8. The researcher judges other situations that may affect the clinical research and the judgment of research results;